SEEKYO

Seekyo is a privately-owned biotech company that develops the next generation of chemotherapies By targeting the microenvironment of solid tumors while sparing healthy tissues, our aim is to provide treatments without adverse effects to cancer patients. Seekyo’s Smart Drugs transport potent anticancer agents in an innocuous manner toward safe tissues, provide efficient recognition of malignant specificities thanks to its targeting unit and allow the controlled release of the parent drug exclusively at the tumour site, based on its versatile enzyme-responsive self-immolative linker.